Trial
NCT02808247
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Boehringer Ingelheim
Condition
Sarcoma, Soft Tissue
Intervention
Nintedanib
Why stopped
Exceed of pre-specified number of failures in the experimental arm
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-20